Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Aeterna's AEZS-108 final Phase 2 results in endometrial cancer to be presented at ESGO 2011

Aeterna Zentaris Inc. today announced that final Phase 2 results in endometrial cancer on its anticancer compound, AEZS-108, will be presented during a poster session at the upcoming 17th International Meeting of the European Society of Gynaecological Oncology, to be held September 11-14, 2011, at the Milan Convention Center in Milan, Italy.

19 Jul 2011

CVS Caremark adds Access' MuGard to pharmacy benefit network

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that its lead product for oral mucositis, MuGard, has been added to CVS Caremark's pharmacy benefit network.

15 Jul 2011

Nature journal publishes landmark genetic study of ovarian cancer

A University of Houston researcher is an author on a landmark multi-institutional genetic study of the most aggressive and common form of ovarian cancer that is published in the current issue of the scientific journal Nature.

11 Jul 2011

Onconova, SymBio enter commercialization collaboration for rigosertib in Japan and Korea

Onconova Therapeutics, Inc., and SymBio Pharmaceuticals Limited announced today that they will collaborate to develop and commercialize rigosertib in Japan and Korea. Onconova is conducting late-stage clinical trials with rigosertib (ON 01910.Na) in the U.S., Europe and India for the treatment of Myelodysplastic Syndromes (MDS) and solid tumors.

8 Jul 2011

Researchers use AFM to characterize ovarian cell structure for cancer diagnosis

Using ovarian surface epithelial cells from mice, researchers from Virginia Tech have released findings from a study that they believe will help in cancer risk assessment, cancer diagnosis, and treatment efficiency in a technical journal: Nanomedicine.

7 Jul 2011

Gene therapy may help prevent progression of type 1 diabetes

Increasing a specific protein in areas of the pancreas that produce insulin blocks the immune attack that causes type 1 diabetes, researchers reported in the August issue of the Journal of Clinical Investigation, published early online.

7 Jul 2011

Ovarian cells are stiffer and more viscous when benign

6 Jul 2011

Ovarian cancer molecular updates

In a new study a genetic mutation was found in the most common form of ovarian cancer. This according to the US scientists could pave the way for a more effective treatment of the disease. The detailed genetic map already helped scientists identify existing drugs with the potential for treating the mutations found in ovarian cancer tumors and also identified mutations that could respond to new drugs.

1 Jul 2011

TCGA examines ovarian serous adenocarcinoma tumors from 500 patients

An analysis of genomic changes in ovarian cancer has provided the most comprehensive and integrated view of cancer genes for any cancer type to date. Ovarian serous adenocarcinoma tumors from 500 patients were examined by The Cancer Genome Atlas (TCGA) Research Network and analyses are reported in the June 30, 2011, issue of Nature.

30 Jun 2011

Researchers develop way to uncover evolution of human cancer cells

A team of researchers led by scientists at the University of California, San Francisco has developed a way to uncover the evolution of human cancer cells, determining the order in which mutations emerge in them as they wend their way from a normal, healthy state into invasive, malignant masses.

30 Jun 2011

RHEI receives Chinese SFDA acceptance letter for MuGard

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, announced that its MuGard partner in China, RHEI Pharmaceuticals has received the acceptance letter from the State Food and Drug Administration (SFDA) of China acknowledging all necessary documentation for the MuGard has been submitted and accepted.

17 Jun 2011

Scientists use time-lapse technique to create lab model for ovarian cancer

Scientists at Harvard University have created a laboratory model using time-lapse video microscopic technology that allows observation of early stages of ovarian cancer metastasis.

15 Jun 2011

UC Davis, Jackson Laboratory and NCI partner for human clinical trials on cancer

About nine out of 10 new cancer drugs successfully clear preclinical development hurdles, but then they fail in human clinical testing. A new partnership facilitated by SAIC-Frederick Inc. aims to help change that outcome.

13 Jun 2011

NYU Cancer Institute scientists present new research findings at ASCO 2011

Experts from The Cancer Institute, an NCI-designated cancer center, at NYU Langone Medical Center presented new research findings at the 47th American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago, IL.

8 Jun 2011

Ovarian cancer screenings do not reduce risk of death

A University of Alabama at Birmingham study released today reports that ovarian cancer screenings do not reduce a woman's risk of death from the disease and the invasive medical procedures may create associated health problems.

7 Jun 2011

Faults in p53 gene could help predict beneficial drug combination for ovarian cancer

FAULTS in a gene commonly inactivated in many different types of cancer could be used to predict which drug combination ovarian cancer patients are most likely to benefit from, according to results presented at the American Society for Clinical Oncology.

7 Jun 2011

ImaginAb, Oxford BioMedicaplc enter research deal to develop in vivo diagnostic imaging agent

Oxford BioMedicaplc, a leading gene therapy company, today announces that it has signed a research collaboration agreement with ImaginAb, Inc., a biotechnology company specialising in the development of engineered antibody fragments for diagnostic imaging and novel therapeutic applications, to engineer an in vivo diagnostic imaging agent using an antibody targeting the Company's proprietary 5T4 tumour antigen.

7 Jun 2011

Tikcro reports net loss of $30,000 for first quarter 2011

Tikcro Technologies Ltd. today reported results for the first quarter ended March 31, 2011.

7 Jun 2011

Encouraging data from Cylene CX-4945 Phase I dose-escalation trial presented at ASCO 2011

Cylene Pharmaceuticals, Inc. today announced the presentation of encouraging data from an ongoing Phase I dose-escalation trial of CX-4945 in patients with solid tumors at the 2011 American Society of Clinical Oncology (ASCO) annual meeting held on June 4-8 in Chicago, IL.

6 Jun 2011

Cancer risk assessment in Lynch syndrome

Among various genetic mutations for individuals with Lynch syndrome, a hereditary cancer syndrome that carries a high risk of colon cancer and an above-normal risk of other cancers, researchers have identified mutations associated with a lower cancer risk and mutations associated with an increased risk for ovarian and endometrial cancer, according to a study in the June 8 issue of JAMA, a theme issue on cancer.

6 Jun 2011